ADSB-FUB-187
id:
adsb-fub-187-180-16964537
title:
ADSB-FUB-187
text:
ADSB-FUB-187 is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.09 nM and an EC50 of 1.09 nM. It was originally developed by Pfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of Ki, it is not the most potent compound at producing a CB1 mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC50 values.
brand slug:
wiki
category slug:
encyclopedia
description:
Synthetic cannabinoid
original url:
https://en.wikipedia.org/wiki/ADSB-FUB-187
date created:
2015-07-08T18:25:19Z
date modified:
2024-09-05T13:49:39Z
main entity:
{"identifier":"Q20707333","url":"https://www.wikidata.org/entity/Q20707333"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/3/36/ADSB-FUB-187.svg","width":1152,"height":1332}
fields total:
13
integrity:
16